The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 629-631

  Ghassabian, Sussan ^a   Chetty, Manoranjenni ^a   Tattam, Bruce N ^a   Glen, John ^b   Rahme, Jeannie ^b   Stankovic, Zvijezdana ^b   Ramzan, Iqbal ^a   Murray, Michael ^a   McLachlan, Andrew J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMHEXINE; CAFFEINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUVOXAMINE; LOSARTAN; LOSARTAN POTASSIUM; MEPRAZOLE; MIDAZOLAM; OMEPRAZOLE; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; LETTER; MENTAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SINGLE DRUG DOSE;

BIOTRANSFORMATION; CLOZAPINE; CYTOCHROME P-450 CYP3A; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHENOTYPE; PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 77957279357     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f03e30     Document Type: Letter

References (19)

1. Agid O, Remington G, Kapur S. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27: 369-373. (Pubitemid 47075508)
2. Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004;11: 297-312. (Pubitemid 38247746)
3. Dain JG, Nicoletti J, Ballard F. Biotransformation of clozapine in humans. Drug Metab Dispos. 1997;25: 603-609. (Pubitemid 27213102)
4. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994;38: 471-473. (Pubitemid 24344037)
5. Haselmo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62: 1049-1053. (Pubitemid 44786497)
6. Kuo F-H, Lane H-Y, Chang W-H. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol. 1998;18: 483-484.
7. Cohen LG, Chesley S, Eugenio L, et al. Erythromycin-induced clozapine toxic reaction. Arch Intern Med. 1996;6: 675-677. (Pubitemid 26095019)
8. Funderburg LG, Vertrees JE, True JE, et al. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry. 1994;12: 1840-1841.
9. Pirmohamed M, Williams S, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272: 984-990.
10. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44: 439-446. (Pubitemid 27485474)
11. Zhang W, D'Esposito F, Edwards R, et al. Interindividual variation in relative CYP1A2/3A4 phenotype influence susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008;36: 2547-2555.
12. Olesen OV, Linnet K. Contribution of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41: 823-832. (Pubitemid 32692092)
13. Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29: 319-326.
14. Ghassabian S, Chetty M, Tattam BN, et al. A high-throughput assay using liquid chromatography tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome P450 enzymes in patients. Ther Drug Monit. 2009;31: 239-246.
15. Aravagiri M, Marder SR. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/ electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J Pharm Biomed Anal. 2001; 25: 301-311. (Pubitemid 32709945)
16. Ryu JY, Song IS, Sunwoo YE, et al. Development of the BInje cocktail[ for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 2007;82: 531-540.
17. Mauri MC, Volonteri LS, Dell Osso B, et al. Predictors of clinical outcomes in schizophrenia patients responding to clozapine. J Clin Psychopharmacol. 2003;23: 660-664.
18. Dailly E, Urien S, Chanut E, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter-and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26: 699-703. (Pubitemid 34615975)
19. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci. 2006;256: 287-293. (Pubitemid 44285052)